Our company’s success lies in our diverse skill mix. The experience and expertise of our Chairman and non executive directors are second-to-none, providing the potential for VisusNano to produce a game- changing technology in the ophthalmic industry.

  • Philip Alexander
    Philip Alexander
    CEO
  • Elodie Siney
    Elodie Siney
    COO
  • Darren Pitt
    Darren Pitt
    CSO
  • Joanna Gould
    Joanna Gould
    CBO
  • Scott Woodward
    Scott Woodward
    Chairman
Philip Alexander
CEO

Philip is a consultant ophthalmologist specialising in cataract and retinal surgery. His doctoral thesis studied innovative techniques for retinal transplantation. Philip has a strong background in research, and has published over 40 peer-reviewed papers. He has an interest in partnerships between academia, industry and healthcare and his MBA thesis focussed on healthcare innovation.

Elodie Siney
COO

Elodie is a research scientist with expertise in human stem cells, completed the integrated PhD programme at the University of Southampton specialising in human stem cells for translational research. Elodie worked in an SME as a chemical analyst and has experience in clinical trials.

Darren Pitt
CSO

Darren completed his PhD titled “Design of polymer systems and surface-active agents for the improvement of cell attachment for treatment of ocular diseases”. Darren is currently the manager in solvent manufacturing having moved from a large scale pharmaceutical manufacturing site, where he was the Technical Process Chemist for the potent drug facility.

Joanna Gould
CBO

Joanna is currently a third year PhD student in developmental Neuroscience at University of Southampton. After her MRes Joanna had a career change and went into corporate banking at Bank of America before deciding to come back to science. Joanna has also worked in research and development at an SME.

Scott Woodward
Chairman

Scott brings nearly 20 years’ experience from healthcare, pharma, and biotech in business development through consulting and senior executive roles in the United States and Europe. He has a proven track record of identifying and building profitable business relationships for scientific companies seeking global biopharma partners and expanding their business development activities. He has deep expertise in in-licensing and out-licensing in bio and pharma. Scott is currently at Ventac Partners, and was Global Vice President of biomarker operations for a US headquartered, multinational CRO.